Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline for Smoking Reduction in Veterans Unwilling to Quit
NCT06966362Phase 4Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Aug 2026
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of varenicline in Tobacco Use Disorder (TUD) (2 arms), sponsored by VA Office of Research & Development. Primary endpoint: 7-day point prevalence abstinence at 6 months. Started Aug 2026; status: recruiting.
02
Drugs
varenicline
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT06966362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06966362.